Test Code Billings Clinic: 8734 Mayo: GLP Glucagon, Plasma
Reporting Name
Glucagon, PPerforming Laboratory

Useful For
Diagnosis and follow-up of glucagonomas and other glucagon-producing tumors
Assessing diabetic patients with problematic hyper- or hypoglycemic episodes (extremely limited utility)
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Specimen Required
Patient Preparation: Patient should fast for 8 hours before specimen collection.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL
Collection Instructions:
1. Pre-chill lavender top (EDTA) tube at 4° C before drawing the specimen.
2. Draw blood into the pre-chilled tube and process as follows:
a. Chill filled tube in wet ice for 10 minutes.
b. Centrifuge in a refrigerated centrifuge or in a pre-chilled centrifuge carrier.
c. Immediately after centrifugation, aliquot plasma into a plastic vial and freeze.
Specimen Type
Plasma EDTASpecimen Minimum Volume
0.45 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Plasma EDTA | Frozen | 90 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
≥1 year of age: ≤159 pg/mL
<1 year of age: No reference interval established.
For International System of Units (SI) for Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html.
Interpretation
Elevated glucagon concentrations in the absence of hypoglycemia may indicate the presence of a glucagon-secreting tumor. Successful treatment of a glucagon-secreting tumor is associated with normalization of glucagon levels.
Inappropriate elevations in glucagon concentrations in patients who are hyperglycemic and have type I diabetes indicate that paradoxical glucagon release may contribute to disease severity. This can be observed if insulin treatment is inadequate and patients are ketotic. However, glucagon measurement plays little, if any, role in the diagnostic workup of diabetic ketoacidosis.
In patients with diabetes, low glucagon concentrations (undetectable or in the lower quartile of the normal range) in the presence of hypoglycemia indicate impairment of hypoglycemic counter regulation. These patients may be particularly prone to recurrent hypoglycemia. This can be a permanent problem due to islet alpha-cell destruction or other, less well understood processes (eg, autonomous neuropathy). It can also be functional, most often due to over-tight blood glucose control and may be reversible after decreasing insulin doses.
Day(s) Performed
Tuesday, Friday
Report Available
3 to 7 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82943
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
GLP | Glucagon, P | 2338-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
9358 | Glucagon, P | 2338-2 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.